A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)

drug protocol number

GB002-3101

drug sponsor

Gossamer Bio

drug study

Seralutinib

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)

drug status

Ongoing

drug phase